Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24526737.
- Also identified by DOI 10.1158/1078-0432.CCR-13-3388.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Disseminated malignant melanoma has a poor prognosis. Immunotherapy based on cytokines or checkpoint inhibitors has a protracted beneficial effect in a select group of patients. Understanding the mechanisms that inhibit tumor-specific T cells will help the development of biomarkers to formulate therapy for this disease. Clin Cancer Res; 20(6); 1401-3. ©2014 AACR.
Medical subject headings
- Immune Tolerance
- Immunotherapy
- Melanoma
- Myeloid Cells
- T-Lymphocytes